TuHURA Biosciences Files 8-K for Material Agreement
Ticker: HURA · Form: 8-K · Filed: Nov 4, 2025 · CIK: 1498382
Sentiment: neutral
Topics: material-agreement, 8-k, company-name-change
TL;DR
TuHURA Bio (formerly Kintara) signed a material deal, check the 8-K for details.
AI Summary
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K on November 4, 2025, reporting a material definitive agreement entered into on November 3, 2025. The filing also includes financial statements and exhibits. The company is incorporated in Nevada and its principal executive offices are located in Tampa, Florida.
Why It Matters
This 8-K filing indicates TuHURA Biosciences has entered into a significant agreement, which could impact its business operations and future financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that may affect the company's stock price.
Key Players & Entities
- TuHURA Biosciences, Inc. (company) — Registrant
- Kintara Therapeutics, Inc. (company) — Former company name
- November 3, 2025 (date) — Date of earliest event reported
- November 4, 2025 (date) — Date of report
- Nevada (jurisdiction) — State of incorporation
- Tampa, Florida (location) — Principal executive offices
FAQ
What is the nature of the material definitive agreement TuHURA Biosciences entered into?
The filing states that TuHURA Biosciences entered into a material definitive agreement on November 3, 2025, but the specific details of the agreement are not provided in the summary information.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted on November 4, 2025.
What was TuHURA Biosciences, Inc. formerly known as?
TuHURA Biosciences, Inc. was formerly known as Kintara Therapeutics, Inc.
Where are TuHURA Biosciences, Inc.'s principal executive offices located?
TuHURA Biosciences, Inc.'s principal executive offices are located at 10500 University Center Dr., Suite 110, Tampa, Florida 33612.
What is the SIC code for TuHURA Biosciences, Inc.?
The Standard Industrial Classification (SIC) code for TuHURA Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 985 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2025-11-04 07:00:28
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share HURA The Nasdaq
- $50,000,000 — ng an aggregate offering price of up to $50,000,000 through Wainwright as its sales agent.
- $75,000 — ng Agreement in an amount not to exceed $75,000 in the aggregate. The Company is not
Filing Documents
- hura-20251103.htm (8-K) — 58KB
- 0001193125-25-263523.txt ( ) — 170KB
- hura-20251103.xsd (EX-101.SCH) — 30KB
- hura-20251103_htm.xml (XML) — 5KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. On November 3, 2025, TuHURA Biosciences, Inc. (the "Company") entered into an At The Market Offering Agreement (the "Offering Agreement") with H.C. Wainwright & Co., LLC ("Wainwright") with respect to an at the market offering program under which the Company may offer and sell shares of its common stock, $0.001 par value ("Common Stock"), having an aggregate offering price of up to $50,000,000 through Wainwright as its sales agent. The shares of Common Stock to be offered and sold under the Offering Agreement will be offered and sold pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-291239), which was filed with the Securities and Exchange Commission ("SEC") on November 3, 2025 (the "Registration Statement"). A prospectus supplement related to this at the market offering program with Wainwright was filed as part of the Registration Statement on November 3, 2023. No shares of Common Stock may be sold pursuant to the Offering Agreement until the Registration Statement has been declared effective by the SEC. Sales of the shares of Common Stock, if any, will be made in "at the market offerings" as defined in Rule 415 under the Securities Act of 1933, as amended (the "Securities Act"). Wainwright will use commercially reasonable efforts to sell the shares of Common Stock. The Company will pay Wainwright a cash commission of 3.0% of the gross sales price of the shares of Common Stock that Wainwright sells pursuant to the Offering Agreement. In addition, the Company has agreed to reimburse Wainwright for the documented fees and costs of its legal counsel reasonably incurred in connection with entering into the transactions contemplated by the Offering Agreement in an amount not to exceed $75,000 in the aggregate. The Company is not obligated to sell any of the shares of Common Stock under the Offering Agreement and no assurance can be given that the Company will sell any shares of C
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 At The Market Offering Agreement, dated November 3, 2025, between TuHURA Biosciences, Inc. and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 1.2 to the Registration Statement on Form S-3 filed by the Company on November 3, 2025) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TUHURA BIOSCIENCES, INC. Date: November 4, 2025 By: /s/ Dan Dearborn Name: Dan Dearborn Title: Chief Financial Officer